US focuses pharma supply chain scrutiny


The US Food and Drug Administration (FDA) has named 13 companies that will be allowed to import drug products into the US with reduced scrutiny. Each company will be permitted to import up to five products under expedited entry arrangements for a period of two years.

The FDA’s Secure Supply Chain Pilot Program is an effort to free up the agency’s resources to focus on areas where imports pose the greatest risk to patients and consumers. The scheme rewards manufacturers for voluntarily adopting best practice and integrating integrity and security into their supply chain operations.

The move comes in the wake of a string of product recalls and import bans as some elements of the pharma industry struggle to maintain appropriate quality standards.


Related Content

Reaching out

22 May 2014 Premium contentFeature

news image

Andy Extance surveys how pharma uses outsourcing in a variety of different ways

Business roundup

28 March 2012 Business

news image

Industry news, April 2012

Most Read

Isotope effect produces new type of chemical bond

22 October 2014 Research

news image

Evidence emerges for vibrational bond first proposed 30 years ago

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines

Most Commented

UCLA spent $4.5 million on legal costs in Sangji case

20 October 2014 News and Analysis

news image

University defends spending in case brought against chemistry professor, highlighting $20 million investment in lab safety

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines